| |
Forest Laboratories, Inc.
Corporate Headquarters:
Address: 909 Third Avenue
New York, NY 10022
Phone: (212) 421-7850
Fax: (212) 750-9152
Web Page: www.frx.com
Statistics:
Industry: Pharmaceuticals
Ownership: Public (NYSE:FRX)
Stock Symbol: FRX
FY’05 Net Revenues: $3,159,639
Employees: 5,000+ (global)
Profile:
Forest Laboratories is a pharmaceutical developer, manufacturer and marketer offering prescription medications that have a meaningful impact on people’s lives. Based in New York City with a national sales force and operations in New York, New Jersey, Missouri, Ohio and Europe, Forest’s quest to deliver quality products is driven by entrepreneurial spirit, commitment to integrity and deep respect for people and community.
Forest has well-established franchises in therapeutic areas of the central nervous, cardiovascular and respiratory systems, and is always exploring new product opportunities that address a range of health conditions. Forest’s principal marketed products include Lexapro® (escitalopram oxalate) a selective serotonin reuptake inhibitor (SSRI) for the treatment of depression and anxiety in adults; Namenda® (memantine HCl) for the treatment of moderate to severe Alzheimer’s disease; Benicar® (olmesartan medoxomil) an angiotensin receptor blocker (ARB) for the treatment of hypertension; Campral® (acamprosate calcium) for treating alcohol dependence and Combunox™ (oxycodone HCl and ibuprofen) for short-term management of acute, moderate to severe pain.
Alongside this thriving product portfolio, Forest is developing a flourishing pipeline of compounds in diverse therapeutic areas such as cardiovascular, central nervous system (CNS), pulmonary, , gastrointestinal and inflammation.
News:
http://www.frx.com/news/
Collaborations:
• With H. Lundbeck A/S for Celexa and Lexapro
• With ChemoCentryx, Inc. for the development of agents that target autoimmune and inflammatory diseases
• With Sankyo Pharma Inc. to co-promote Benicar and Benicar HCT® (olmesartan medoxomil — hydrochlorothiazide)
• With Merz Pharmaceuticals for Namenda, the only drug approved to treat moderate and severe Alzheimer’s disease
• With Merck KGaA for Campral the first treatment approved in nearly a decade for alcohol dependence
• With Cypress Bioscience for the development of milnacipran for the treatment of Fibromyalgia.
• With Gedeon Richter for CNS compounds
• With Glenmark Pharmaceuticals for a development compound to potentially treat asthma and chronic obstructive pulmonary disease (COPD)
back to top
|
|
